Pembrolizumab Prior to Surgery for Stage 1B, 2 or 3A Non-small Cell Lung Cancer (NSCLC): A Phase II Study
Phase of Trial: Phase II
Latest Information Update: 28 Jul 2017
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms TOP 1501
- 10 Jun 2017 Biomarkers information updated
- 27 Jan 2017 Status changed from not yet recruiting to recruiting.
- 16 Aug 2016 Planned End Date changed from 1 Nov 2024 to 1 Jan 2027.